Levofloxacin For The Management Of Patients With Abnormal Prostate Specific Antigen (PSA)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

240 participants

Study Classification

INTERVENTIONAL

Study Start Date

2005-03-31

Study Completion Date

2007-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Multicentric, national, prospective, parallel group, controlled. The Subjects in every center will be randomized and assigned to the pharmacologic arm or the one with the biochemical monitoring

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Levofloxacin, Chronic Bacterial Prostatitis

NCT00277511

Prostatitis

COMPLETED PHASE3

An Effectiveness and Safety Study for Levofloxacin in Chronic Prostatitis

NCT00402688

Prostatitis

COMPLETED PHASE3

Non Interventional Study of Levofloxacin in Chronic Prostatitis

NCT02711943

Chronic Prostatitis

COMPLETED

Impact of Antibiotic Treatment on Prostate-Specific Antigen (PSA) Variability

NCT00596453

Prostate Infections

TERMINATED PHASE4

Randomized Trial of Ciprofloxacin Versus Observation for Men With Elevated Prostate Specific Antigen (PSA)

NCT00840294

Elevated Prostate Specific Antigen

TERMINATED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Prostatic Hyperplasia Prostatitis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Levofloxacin oral tablets

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Only subjects who meet all of the following criteria will be eligible to participate in this study:

* Male patients
* Age ≥ 45 years
* Suspected presence of prostate inflammatory foci, defined according to the following criteria:
* PSA ≥ 2.6 ng/mL and age ≥ 50 and \< 60 years (or ≥ 45 years if the patient has known family predisposition to carcinoma of the prostate) or,
* PSA ≥ 4.1 ng/mL and age ≥ 60 and \< 75 years, and
* normal digito-rectal examination (DRE) (see section 5.2), and normal urine test with dipstick and/or microscopy carried out within 5 days of the baseline visit
* Patients willing and able to provide their written informed consent and to comply with study procedures.

* Patients with LUTS/BPH on watchful waiting or already under treatment with alpha-blockers or 5-ARI (5-alpha reductase inhibitors) for at least 6 months will also be considered eligible to participate in the study.

Exclusion Criteria

Patients who meet any of the following criteria will not be eligible to participate in this study:

* Diagnosis of NIH class I-III prostatitis or clinical evidence of active acute urinary infection and/or known or suspected active bacterial infection at other sites;
* Diagnosis of prostate carcinoma (or PIN or ASAPS) or prior radical prostatectomy or radiotherapy or other treatments for prostate cancer;
* PSA \> 20 ng/mL;
* PSA values (including high values) stable over time;
* Start of a pharmacological therapy with 5-ARI in subjects with LUTS/BPH;
* Permanent catheter;
* Prior treatment (within 4 weeks) with levofloxacin for genital-urinary infections;
* Known or suspected allergy to levofloxacin, including the excipients contained in the pharmacological preparation and/or confirmed tendency to photosensitivity reactions after fluoroquinolone therapy;
* Concomitant treatment with drugs not allowed in the study
* Reluctance to undergo prostate biopsy and/or risk of non-compliance;
* History or current evidence of alcohol or drug abuse in the last 12 months;
* History of any conditions that, in the opinion of the investigator, may confound the study results or create additional risks for the patient.
* Participation in any study of investigational or marketed drugs within 30 days before the baseline visit or during the study.

Minimum Eligible Age

45 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

No